Vaxcellbio Secures Japanese Patent for Anti–PD-L1 CAR-T Therapy

Hwasun, Korea - Vaxcellbio, a leading immuno-oncology company, announced on Monday that it has successfully secured a Japanese patent for its anti–PD-...

2026.01.19 08:37

Vaxcellbio Secures Australian Patent for Core NK Cell Expansion Technology

Hwasun, South Korea - Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a biotechnology company specializing in immuno-oncology, announced on Monday that it has ...

2025.10.13 08:53

Vaxleukin-15 Approved as the World’s First Immunotherapy Adjunct for Canine Lymphoma

Hwasun, South Korea - Vaxcellbio (CEO Je-Jung Lee), a biotechnology company specializing in immuno-oncology, announced on Wednesday that Vaxleukin-15 ...

2025.09.18 11:22

Vaxcellbio’s Dual-Target CAR-T project Selected for the National Cancer Center’s Program

Hwasun, Jeollanam-do, Korea - Vaxcellbio (CEO Je-Jung Lee), a biotechnology company specializing in immuno-oncology, announced on ?? that it has been ...

2025.08.25 08:52

Vaxcellbio Secures Foundational Patent for NK Cell-Based Liver Cancer Therapy in Korea

Vaxcellbio, a biotechnology company specializing in cancer immunotherapy, announced today that it has been granted a key domestic patent covering its ...

2025.04.22 14:01